The story so far for the CORE NK trial with Case Western in respect to blood cancers:
- 100% disease control rate (n=4)2/4 patients with a complete response
- 100% CR for AML patients with max dosage of CORE NK + Vactosertib combo (n=1)
- excellent safety profile
Please be mindful that during Phase 1A dose escalation means some patients are not treated with the max dosage. Also combo therapies are super common! In this case, Vactosertib is used to modulate the blood cancer microenvironment so that the NK cells can do their thing!
The story so far for the CORE NK trial with Case Western in...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $69.39K | 17.34M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 40 | 26298938 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 9474957 | 10 |
View Market Depth
| Last trade - 11.21am 18/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |